The boss’s plan: New Genmab a force to be reckoned with
The days of being left behind with a minimal share of medicine sales have gone by. With the first black numbers ever and money to spend, Genmab is headed into a new phase, set to earn the Danish biotech a higher place in the pharma hierarchy, according to the CEO.
by Leonora Beck
Genmab will no longer be content to be the small fishin the pond bending to the will of Big Pharma; the Danish biotech company should take control of negotiations when future profits have to be secured, CEO Jan van de Winkel believes.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab CEO: Preparing the company for the future
For abonnenter
Analyst: The market overestimates Arzerra
For abonnenter
”It enables a whole new business model”
For abonnenter
